Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases (DIAID).
J Infect Dis. 2014 Mar 1;209(5):729-33. doi: 10.1093/infdis/jit418. Epub 2013 Aug 2.
In this prospective study, human immunodeficiency virus type 1 (HIV-1)-infected subjects underwent QuantiFERON-TB Gold In-Tube interferon-γ release assay (IGRA) testing at baseline and after 24 months in a low tuberculosis incidence country. Concordant baseline and follow-up results were observed in 86% (n = 686 of 794) of subjects. IGRA conversions occurred in 9% (n = 63 of 718), whereas IGRA reversions were seen in 33% (n = 25 of 76) of individuals. Of the 10 active tuberculosis cases during follow-up, 5 had concordant positive IGRA results and 2 were IGRA converters. Although the clinical significance of IGRA conversions and reversions remains to be established, repeated IGRA testing seems to be of value in HIV-1-infected individuals.
在这项前瞻性研究中，在低结核病发病率国家，人类免疫缺陷病毒 1 型（HIV-1）感染受试者在基线和 24 个月时进行了 QuantiFERON-TB Gold In-Tube 干扰素-γ释放试验（IGRA）检测。86%（794 例中的 686 例）受试者的基线和随访结果一致。IGRA 转化发生在 9%（718 例中的 63 例），而 IGRA 逆转发生在 33%（76 例中的 25 例）。在随访期间的 10 例活动性肺结核病例中，有 5 例 IGRA 结果一致阳性，2 例为 IGRA 转化者。虽然 IGRA 转化和逆转的临床意义仍有待确定，但重复进行 IGRA 检测似乎对 HIV-1 感染者有价值。
